GP Shared Care Decision Support · Australian Guidelines
Diagnostic thresholds · Always visible
| First trimester HbA1c | ≥ 41 mmol/mol (5.9%) |
| OGTT fasting | ≥ 5.1 mmol/L |
| OGTT 1-hour | ≥ 10.0 mmol/L |
| OGTT 2-hour | ≥ 8.5 mmol/L |
| BGL targets — fasting | ≤ 5.0 mmol/L |
| BGL targets — 1hr post-meal | ≤ 7.4 mmol/L |
| Hypertension | ≥ 140/90 mmHg |
| Significant rise | +30/15 mmHg from baseline |
| Proteinuria (PCR) | ≥ 30 mg/mmol |
| Dipstick protein | ≥ 2+ |
| Aspirin prophylaxis | 100–150mg nocte from 12w |
| PlGF screening | 11+0 to 13+6 weeks |
| Hb (T1 / T3) | < 105 g/L |
| Hb (T2) | < 110 g/L |
| Iron deficiency (ferritin) | < 30 µg/L |
| Oral iron (deficiency anaemia) | 100–200mg elemental/day |
| Oral iron (deficiency w/o anaemia) | 20–80mg elemental/day |
| IV iron — consider if | Hb <100 >36w OR Hb <90 >32w |
| Free fetal DNA Rh D | From 15 weeks |
| Sensitising event <12w | 250 IU (625 if multiple) |
| Sensitising event ≥12w | 625 IU + FMH ≥20w |
| Routine prophylaxis | 625 IU at 28 + 34 weeks |
| Postnatal (baby Rh+) | 625 IU within 72h |
| Repeat antibody screen | Before 28w dose |
| Dating USS (ideal) | 7–8w (CRL ≥10mm) |
| NIPT (blood) | From 10 weeks |
| CFTS bloods (PAPP-A, βhCG) | 10+0 to 13+6w |
| Nuchal translucency USS | 11+3 to 13+6w |
| PlGF (early PE screen) | 11+0 to 13+6w |
| Free fetal DNA Rh D (if Rh−) | From 15 weeks |
| Morphology USS | 18–22 weeks |